A Clinical Research Study
for Metastatic Pancreatic
Adenocarcinoma (PDAC)

Speak with your doctor to better understand your classification, but generally people diagnosed with metastatic PDAC who have not received previous anti-cancer therapy are considered first line.

Atebimetinib is designed to block MEK, an important “control switch” in the MAPK pathway. This pathway helps tell cells when to grow and divide. In many cancers, the MAPK pathway is stuck in the “on” position, which can cause cancer cells to grow out of control. This happens in many tumor types, including about 97% of pancreatic cancers.

Some drugs in development specifically target RAS mutations. These drugs are designed to block certain abnormal RAS proteins that help turn on the MAPK pathway. Atebimetinib works differently. Instead of targeting RAS directly, it targets MEK, which sits farther down the same pathway. Because of MEK’s central position in the pathway, atebimetinib may help shut down MAPK pathway signaling and block cancer growth in a broader range of tumors than drugs that only target specific RAS mutations. This creates the potential for more lasting treatment benefit in cancers that depend on this pathway.

A clinical trial is a research study where new treatments, like medicines, are tested to see if they can help people with specific health issues (like cancer). These trials compare new potential treatments against medicines that are currently in use.